Proteotype Diagnostics
Proteotype Diagnostics
  • Home
  • Platform
  • Enlighten
  • Newsroom
  • About Us
  • Contact Us
  • More
    • Home
    • Platform
    • Enlighten
    • Newsroom
    • About Us
    • Contact Us
  • Sign In

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • Platform
  • Enlighten
  • Newsroom
  • About Us
  • Contact Us

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

A new class of test, Registered with the mhra

  1. Addressing a high unmet need
  2. Technology that is available now
  3. Affordable and high performance
  4. Accessible distributed diagnostic
  5. Detecting solids tumours earlier
  6. Under clinical validation

MODERNISED

MODERNISED is our two-year, NIHR (National Institute for Health and Care Research) / Office for Life Sciences-funded (Department of Health and Social Care and Department for Science, Innovation and Technology) clinical study led by the Southampton Clinical Trials Unit and Proteotype Diagnostics. The trial will enrol 1,350 volunteers across southern-England NHS hospitals to validate Enlighten®. MODERNISED aims to lay the groundwork for a scalable multi-cancer screening programme in the NHS

1. Addressing A high unmet need

2. Technology that is Available Now

2. Technology that is Available Now

It is estimated that one in two people will be diagnosed with some form of cancer within their lifetime (1). 70% of cancer deaths occur from cancers without available screening (2).

2. Technology that is Available Now

2. Technology that is Available Now

2. Technology that is Available Now

Enlighten® is a first-in-class Multi-Cancer Early Detection test that measures the host response to tumour development, strongest in early-stage cancers, using an affordable, fluorescence-kit-based microplate reader assay. 

3. Affordable and High PerforMance

2. Technology that is Available Now

Our biorthogonal chemistry enables direct measurement of the host response from crude patient plasma, eliminating complex sample preparation. Enlighten® is built for real-word adoption.

4. Accessible Distributed diagnostic

Our unique technology allows whole blood samples to remain at room temperature in

common and inexpensive standard EDTA collection tubes for up to 48 hours before processing into plasma. This enables accessible sample collection in distributed settings (pharmacies and mobile vans).

5. detecting solid tumours earlier

5. detecting solid tumours earlier

MODERNISED is evaluating Enlighten® in Breast, Colorectal, Prostate, Pancreatic, Lung, Melanoma, Oesophageal, Ovarian, Bladder, and Renal cancer.  

6. Under Clinical Validation

5. detecting solid tumours earlier

MODERNISED: A prospective observational study to generate evidence on the performance characteristics of Enlighten®, and to design a NHS programme for the use of the test, providing acceptable, effective, equitable, and cost-effective screening.

Copyright © 2025 Proteotype Diagnostics - All Rights Reserved.

Patent Pending in 19 Jurisdictions

Disclaimer: For Performance Evaluation Only - Not For Diagnostic Use.

  • Platform
  • Enlighten
  • About Us
  • Contact Us

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept